STOCK TITAN

NovoCure (NASDAQ: NVCR) ex-CEO uses 17,638 shares to cover RSU taxes

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovoCure Ltd reported that former Chief Executive Officer Ashley Cordova had 17,638 ordinary shares withheld on March 4, 2026 to cover tax obligations tied to vesting Restricted Stock Units. The shares were withheld by the issuer at $13.30 per share in a non-discretionary, tax-withholding disposition. After this transaction, Cordova directly owned 422,570 ordinary shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cordova Ashley

(Last) (First) (Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)
WAYNE PA 19087

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Former Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/04/2026 F 17,638(1) D $13.3 422,570 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).
Remarks:
Steven Robbins, as attorney in fact for Cordova, Ashley 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NovoCure Ltd (NVCR) report for Ashley Cordova?

NovoCure reported that former CEO Ashley Cordova had 17,638 ordinary shares withheld to satisfy tax obligations from vesting Restricted Stock Units. The issuer withheld these shares as a non-discretionary tax-withholding disposition, rather than an open-market sale.

Was Ashley Cordova’s NovoCure (NVCR) Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. NovoCure withheld 17,638 shares to cover tax withholding obligations upon RSU vesting, a non-discretionary disposition approved under Rules 16b-3(e) and 16b-3(d)(1).

How many NovoCure (NVCR) shares were involved in Ashley Cordova’s tax withholding?

The transaction involved 17,638 NovoCure ordinary shares. These shares were withheld by the company at $13.30 per share to cover tax obligations arising from the vesting of Restricted Stock Units awarded to Ashley Cordova.

What is Ashley Cordova’s NovoCure (NVCR) share ownership after this Form 4 transaction?

After the tax-withholding disposition, Ashley Cordova directly owned 422,570 NovoCure ordinary shares. This figure reflects her position following the issuer’s withholding of 17,638 shares for RSU-related tax obligations.

Why did NovoCure (NVCR) withhold shares from Ashley Cordova’s RSU vesting?

NovoCure withheld 17,638 shares from Ashley Cordova to cover required tax withholding obligations triggered by vesting Restricted Stock Units. The transaction was non-discretionary and approved under applicable Rule 16b-3 provisions governing such insider equity-related tax payments.
Novocure

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Latest SEC Filings

NVCR Stock Data

1.49B
100.73M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
Switzerland
ST. HELIER